FULCRUM THERAPEUTICS, INC. (FULC) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$29.31M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$22.19M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$21.86M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$19.82M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$29.31M | (m) | (m) | (m) | $108.00K* | -$16.04M* | (m) | $12.44M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$22.19M | (m) | (m) | (m) | $8.00K | -$18.75M | (m) | $14.08M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$21.86M | (m) | (m) | (m) | $90.00K* | -$14.19M* | (m) | $14.30M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$19.82M | (m) | (m) | (m) | $65.00K* | -$13.82M* | (m) | $12.99M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$20.40M | (m) | (m) | (m) | $0.00 | -$15.26M | (m) | $13.40M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$25.13M | (m) | (m) | (m) | $19.00K* | -$19.07M* | (m) | $14.64M | (m) | (m) |
| 2024-06-30 | Reported | (m) | $52.49M | (m) | (m) | (m) | $0.00* | $58.90M* | (m) | $17.26M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$29.83M | (m) | (m) | (m) | $28.00K | -$25.28M | (m) | $19.77M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$27.44M | (m) | (m) | (m) | $65.00K* | -$22.91M* | (m) | $18.24M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$27.29M | (m) | (m) | (m) | $195.00K* | -$20.79M* | (m) | $17.85M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$27.94M | (m) | (m) | (m) | $171.00K | -$24.12M | (m) | $16.71M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$24.36M | (m) | (m) | (m) | $283.00K* | -$27.88M* | (m) | $15.37M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$34.23M | (m) | (m) | (m) | $1.32M* | -$27.37M* | (m) | $25.02M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$26.00M | (m) | (m) | (m) | $246.00K | -$22.11M | (m) | $17.83M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$20.77M | (m) | (m) | (m) | $367.00K* | -$22.57M* | (m) | $17.08M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$19.68M | (m) | (m) | (m) | $565.00K* | -$17.82M* | (m) | $17.38M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$17.04M | (m) | (m) | (m) | $262.00K | -$16.23M | (m) | $16.33M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$19.10M | (m) | (m) | (m) | $93.00K* | -$4.50M* | (m) | $15.64M | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$15.92M | (m) | (m) | (m) | $210.00K* | -$14.12M* | (m) | $12.78M | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$18.80M | (m) | (m) | (m) | $567.00K | -$15.20M | (m) | $14.48M | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$17.01M | (m) | (m) | (m) | $214.00K* | -$13.02M* | (m) | $13.50M | (m) | (m) |
| 2019-06-30 | Reported | (m) | -$13.49M | (m) | (m) | (m) | $221.00K* | -$12.07M* | (m) | $10.86M | (m) | (m) |
| 2019-03-31 | Reported | (m) | -$37.23M | (m) | (m) | (m) | $310.00K | -$9.90M | (m) | $34.63M | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$9.09M | (m) | (m) | (m) | $926.00K* | -$4.12M* | (m) | $6.96M | (m) | (m) |
| 2018-06-30 | Reported | (m) | -$7.85M | (m) | (m) | (m) | (m) | (m) | (m) | $5.79M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$84.77M | (m) | (m) | (m) | $314.00K | -$60.06M | (m) | $56.10M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$21.90M | (m) | (m) | (m) | $278.00K | -$2.22M | (m) | $63.39M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$110.66M | (m) | (m) | (m) | $508.00K | -$90.97M | (m) | $71.80M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$112.56M | (m) | (m) | (m) | $1.96M | -$97.05M | (m) | $76.78M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$81.05M | (m) | (m) | (m) | $1.71M | -$78.48M | (m) | $69.70M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$71.61M | (m) | (m) | (m) | $1.34M | -$53.66M | (m) | $59.04M | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$84.22M | (m) | (m) | (m) | $853.00K | -$39.48M | (m) | $71.07M | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$33.50M | (m) | (m) | (m) | $8.98M | -$22.56M | (m) | $25.18M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |